Appendix Neuroendocrine Tumor
Associated Genetic Biomarkers
NCI Definition: A well differentiated, low or intermediate grade tumor with neuroendocrine differentiation that arises from the appendix. 
Appendix neuroendocrine tumors most frequently harbor alterations in SMAD4, KRAS, YES1, SPOP, and SMARCA4 .
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, YES1 Loss, and SPOP Y87C are the most common alterations in appendix neuroendocrine tumor .
There are 3 clinical trials for appendix neuroendocrine tumor, of which 3 are open and 0 are completed or closed. Of the trials that contain appendix neuroendocrine tumor as an inclusion criterion, 3 are phase 2 (3 open).
SSTR1, SSTR2, and SSTR3 are the most frequent gene inclusion criteria for appendix neuroendocrine tumor clinical trials .
177lu-dota-octreotate, abemaciclib, and capecitabine are the most common interventions in appendix neuroendocrine tumor clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.